

# CITATION REPORT

List of articles citing

Clinical pharmacokinetics and pharmacodynamics of carvedilol

DOI: 10.2165/00003088-199426050-00002  
Clinical Pharmacokinetics, 1994, 26, 335-46.

**Source:** <https://exaly.com/paper-pdf/25418515/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
142	Comparison of the Hummel-Dreyer method in high-performance liquid chromatography and capillary electrophoresis conditions for study of the interaction of (RS)-, (R)- and (S)-carvedilol with isolated plasma proteins. <b>1996</b> , 682, 349-57		34
141	Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. <b>1997</b> , 54, 161-85		71
140	Effects of a hydroxylated metabolite of the beta-adrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury. <b>1998</b> , 123, 292-8		15
139	Carvedilol. <b>1998</b> , 339, 1759-65		208
138	Clinical pharmacokinetics of vasodilators. Part II. <i>Clinical Pharmacokinetics</i> , <b>1998</b> , 35, 9-36	6.2	56
137	Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. <b>1999</b> , 33, 1266-9		13
136	Pharmacological interference of vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. <b>1999</b> , 386, 317-21		1
135	Effects of food on clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1999</b> , 37, 213-55	6.2	249
134	Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. <b>2000</b> , 40, 844-53		58
133	Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. <b>2000</b> , 60, 69-76		51
132	Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. <b>2001</b> , 37, 678-91		15
131	Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. <b>2001</b> , 755, 111-7		24
130	Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 505-16	6.2	56
129	Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. <b>2002</b> , 16, 373-80		51
128	Provoked bradycardia after paroxetine administration. <b>2003</b> , 25, 142-4		3
127	Liquid chromatographic determination of carvedilol in human plasma. <b>2003</b> , 789, 405-10		42
126	Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. <b>2003</b> , 55, 382-8		11

125	Carvedilol: a review of its use in chronic heart failure. <b>2003</b> , 63, 1697-741	45
124	Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca <sup>2+</sup> ] <sub>i</sub> in ventricular myocytes compared with those of timolol and atenolol. <b>2003</b> , 67, 83-90	24
123	Long-term oral carvedilol in chronic heart failure. <b>2004</b> , 5, 1359-72	4
122	Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. <b>2004</b> , 9, 117-28	10
121	Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. <b>2004</b> , 1, 82-8	1
120	Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. <b>2004</b> , 10, 496-502	46
119	Clinical pharmacokinetics of once-daily molsidomine. <b>2004</b> , 2, 131-141	10
118	Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. <b>2004</b> , 23, 832-8	80
117	Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. <b>2005</b> , 822, 253-62	36
116	Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. <i>Drug Development and Industrial Pharmacy</i> , <b>2005</b> , 31, 785-94	3.6 128
115	The COMET trial. <b>2005</b> , 11, 39-47	3
114	Carvedilol in chronic heart failure: past, present and future. <b>2005</b> , 1, 723-34	3
113	Are there clinically important differences between beta-blockers in heart failure?. <b>2005</b> , 1, 57-66	1
112	Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. <b>2005</b> , 45, 6-24	16
111	Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?. <b>2006</b> , 22, 709-20	12
110	Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. <b>2006</b> , 106, 199-206	50
109	Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. <b>2006</b> , 17, 731-5	9
108	Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. <b>2001</b> , 19, 152-71	92

107	Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. <b>2006</b> , 58, 521-90		328
106	Development and in vitro evaluation of buccoadhesive carvedilol tablets. <b>2007</b> , 57, 185-97		28
105	Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. <b>2007</b> , 30, 2146-53		26
104	Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. <b>2007</b> , 30, 537-42		34
103	Combined alpha/beta-blockade: an underused approach to the treatment of resistant hypertension. <b>2007</b> , 9, 663-6		4
102	Carvedilol: use in chronic heart failure. <b>2007</b> , 5, 21-31		23
101	New RP-HPLC Method with UV-Detection for the Determination of Carvedilol in Human Serum. <b>2007</b> , 30, 1677-1685		9
100	Evaluation of acrylamide-grafted-xanthan gum copolymer matrix tablets for oral controlled delivery of antihypertensive drugs?. <b>2007</b> , 69, 130-141		106
99	Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. <b>2007</b> , 44, 250-3		45
98	Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol. <i>Drug Development and Industrial Pharmacy</i> , <b>2007</b> , 33, 990-8	3.6	20
97	Stereoselective glucuronidation of carvedilol by Chinese liver microsomes. <b>2007</b> , 8, 756-64		2
96	Severe paroxysmal hypertension (pseudopheochromocytoma). <b>2008</b> , 10, 12-8		29
95	Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. <i>Biopharmaceutics and Drug Disposition</i> , <b>2008</b> , 29, 280-8	1.7	11
94	Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. <b>2008</b> , 589, 194-200		12
93	Development and characterization of a carvedilol-loaded self-microemulsifying delivery system. <b>2009</b> , 26, 50-64		10
92	The clinical spectrum of labile hypertension: a management dilemma. <b>2009</b> , 11, 491-7		11
91	Effect of <i>Asparagus racemosus</i> extract on transdermal delivery of carvedilol: a mechanistic study. <i>AAPS PharmSciTech</i> , <b>2009</b> , 10, 199-210	3.9	17
90	The role of carvedilol in the management of portal hypertension. <b>2010</b> , 22, 905-11		30

89	Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. <b>2010</b> , 33, 1378-84		19
88	(S)-(+)-4-(Oxiran-2-ylmethoxy)-9H-carbazole. <b>2010</b> , 66, o2785		
87	Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases. <b>2010</b> , 6, 237-50		13
86	Asymmetric Membrane Capsules for Extended Delivery of the Weakly Basic Drug Carvedilol. <b>2010</b> , 2, 199-208		5
85	Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. <b>2011</b> , 18, 599-612		68
84	Solid dispersions of carvedilol with porous silica. <b>2011</b> , 59, 427-33		18
83	Drug therapy for resistant hypertension: simplifying the approach. <b>2011</b> , 13, 120-30		29
82	Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. <i>International Journal of Pharmaceutics</i> , <b>2011</b> , 406, 41-8	6.5	105
81	Effects of Glipizide on the Pharmacokinetics of Carvedilol after Oral and Intravenous Administration in Rats. <b>2011</b> , 19, 237-242		2
80	Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes. <b>2012</b> , 90, 117-24		5
79	Evaluation of carbon nanotubes as chiral selectors for continuous-flow enantiomeric separation of carvedilol with fluorescent detection. <b>2012</b> , 70, 631-5		19
78	Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: <i>in vitro</i> , pharmacokinetic and pharmacodynamic investigations. <b>2012</b> , 29, 126-37		16
77	Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. <b>2012</b> , 166, 2277-88		65
76	Mucoadhesive buccal patches based on interpolymer complexes of chitosan-pectin for delivery of carvedilol. <b>2012</b> , 20, 21-7		61
75	Microemulsions for oral administration and their therapeutic applications. <b>2012</b> , 9, 937-51		42
74	Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. <b>2012</b> , 224, 363-76		49
73	Effects of myricetin on the bioavailability of carvedilol in rats. <b>2012</b> , 50, 516-22		12
72	Enantioselective LC/ESI-MS/MS analysis and pharmacokinetic and tissue distribution study of (2RS)-1-(7-methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in rats. <b>2012</b> , 24, 591-9		3

71	Characterization of agglomerated carvedilol by hot-melt processes in a fluid bed and high shear granulator. <i>International Journal of Pharmaceutics</i> , <b>2012</b> , 430, 74-85	6.5	17
70	A simplified mechanistic algorithm for treating resistant hypertension: efficacy in a retrospective study. <b>2012</b> , 14, 191-7		15
69	Crystalline and amorphous carvedilol-loaded nanoemulsions: formulation optimisation using response surface methodology. <b>2013</b> , 8, 971-992		8
68	Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. <b>2013</b> , 102, 3239-51		39
67	Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. <b>2013</b> , 101, 465-74		99
66	Carvedilol. <b>2013</b> , 38, 113-57		21
65	Dispersive liquid-liquid microextraction based on solidification of floating organic droplet followed by spectrofluorimetry for determination of carvedilol in human plasma. <b>2013</b> , 5, 437-48		24
64	Evaluation of carvedilol-loaded microsponges with nanometric pores using response surface methodology. <b>2014</b> , 9, 831-850		13
63	Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. <b>2015</b> , 9, 1379-92		3
62	Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study. <b>2015</b> , 9, 2911-8		4
61	Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. <b>2015</b> , 10, 4797-813		61
60	Effect of particle size on oral absorption of carvedilol nanosuspensions: in vitro and in vivo evaluation. <b>2015</b> , 10, 6425-34		27
59	Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. <b>2015</b> , 13, 627-36		4
58	Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. <i>International Journal of Pharmaceutics</i> , <b>2015</b> , 478, 736-44	6.5	34
57	Determination of Carvedilol Enantiomers in Pharmaceutical Dosages by SBSE-HPLC Based on Diastereomer Formation. <b>2015</b> , 53, 1316-21		9
56	Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement. <b>2015</b> , 115, 359-67		17
55	Catecholamine excess: pseudopheochromocytoma and beyond. <b>2015</b> , 22, 218-23		13
54	Vortex-assisted liquid-liquid-liquid microextraction (VALLLME) technique: A new microextraction approach for direct liquid chromatography and capillary electrophoresis analysis. <b>2015</b> , 143, 394-401		20

53	Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. <i>Drug Development and Industrial Pharmacy</i> , <b>2015</b> , 41, 1661-6	3.6	8
52	Labile and Paroxysmal Hypertension: Common Clinical Dilemmas in Need of Treatment Studies. <b>2015</b> , 17, 99		6
51	Systemic delivery of $\beta$ blockers via transdermal route for hypertension. <b>2015</b> , 23, 587-602		28
50	$\beta$ Blocker Therapy Could Inflate the Diagnosis of Severe Sepsis. <b>2016</b> , 44, e765-6		3
49	The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats. <b>2017</b> , 99, 139-143		4
48	Carvedilol-loaded nanocapsules: Mucoadhesive properties and permeability across the sublingual mucosa. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2017</b> , 114, 88-95	5.7	47
47	Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. <b>2017</b> , 11, 54-65		24
46	Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. <b>2017</b> , 42, 767-779		9
45	Carvedilol and antioxidant proteins in a type I diabetes animal model. <b>2017</b> , 47, 19-29		11
44	Efficient molecularly imprinted polymer as a pipette-tip solid-phase sorbent for determination of carvedilol enantiomers in human urine. <b>2017</b> , 1061-1062, 399-410		32
43	Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models. <b>2017</b> , 100, 301-307		2
42	Severe carvedilol toxicity without overdose - caution in cirrhosis. <i>Clinical Hypertension</i> , <b>2017</b> , 23, 25	4.8	6
41	Amorphous solid dispersions of carvedilol along with pH-modifiers improved pharmacokinetic properties under hypochlorhydria. <i>Biopharmaceutics and Drug Disposition</i> , <b>2018</b> , 39, 232-242	1.7	4
40	Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 118, 176-182	5.1	8
39	Influence of Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e182	4.7	5
38	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. <i>Pharmaceutical Research</i> , <b>2018</b> , 35, 204	4.5	13
37	Neurogenic hypertension: pathophysiology, diagnosis and management. <i>Clinical Autonomic Research</i> , <b>2018</b> , 28, 363-374	4.3	20
36	Improved biopharmaceutical properties of carvedilol employing $\beta$ tocopheryl polyethylene glycol 1000 succinate-based self-emulsifying drug delivery system. <i>Drug Development and Industrial Pharmacy</i> , <b>2018</b> , 44, 1838-1844	3.6	8

35	Labrasol-Enriched Nanoliposomal Formulation: Novel Approach to Improve Oral Absorption of Water-Insoluble Drug, Carvedilol. <i>AAPS PharmSciTech</i> , <b>2018</b> , 19, 2961-2970	3.9	17
34	Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case. <i>GE Portuguese Journal of Gastroenterology</i> , <b>2019</b> , 26, 196-201	1.1	4
33	Spray-dried carvedilol-loaded nanocapsules for sublingual administration: Mucoadhesive properties and drug permeability. <i>Powder Technology</i> , <b>2019</b> , 354, 348-357	5.2	7
32	Racemic Salts and Solid Solutions of Enantiomers of the Antihypertensive Drug Carvedilol. <i>Crystal Growth and Design</i> , <b>2019</b> , 19, 4498-4509	3.5	6
31	Solidification of carvedilol loaded SMEDDS by swirling fluidized bed pellet coating. <i>International Journal of Pharmaceutics</i> , <b>2019</b> , 566, 89-100	6.5	11
30	SCC4 cell monolayers as an alternative sublingual barrier model: influence of nanoencapsulation on carvedilol transport. <i>Drug Development and Industrial Pharmacy</i> , <b>2019</b> , 45, 63-66	3.6	2
29	Ionic Liquid Forms of Carvedilol: Preparation, Characterization, and Solubility Studies. <i>Journal of Pharmaceutical Innovation</i> , <b>2019</b> , 14, 382-390	1.8	4
28	Genetic Variation of Hepatic Enzymes Influence on $\beta$ -Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure. <i>Journal of Pharmacy Practice</i> , <b>2020</b> , 33, 96-98	1.3	2
27	Sublingual tablets containing spray-dried carvedilol-loaded nanocapsules: development of an innovative nanomedicine. <i>Pharmaceutical Development and Technology</i> , <b>2020</b> , 25, 1053-1062	3.4	2
26	Determination and Comparison of the Solubility, Oil-Water Partition Coefficient, Intestinal Absorption, and Biliary Excretion of Carvedilol Enantiomers. <i>AAPS PharmSciTech</i> , <b>2021</b> , 22, 43	3.9	2
25	Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2021</b> , 163, 240-251	5.7	3
24	Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , <b>2021</b> ,	3.1	0
23	Amorphous Form of Carvedilol Phosphate-The Case of Divergent Properties. <i>Molecules</i> , <b>2021</b> , 26,	4.8	0
22	$\beta$ -Blockers. <b>2014</b> , 233-251		1
21	Carvedilol in hypertension treatment. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 23-30	4.4	52
20	Novel treatment approaches in hypertensive type 2 diabetic patients. <i>World Journal of Diabetes</i> , <b>2014</b> , 5, 536-45	4.7	6
19	Effects of Silibinin on the Pharmacokinetics of Carvedilol after Oral Administration in Rats. <i>Journal of Pharmaceutical Investigation</i> , <b>2011</b> , 41, 153-159	6.3	3
18	Drug Loss due to Grinding, Sifting and Automatic Packaging of Carvedilol Tablets. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2006</b> , 32, 420-423	0.1	0



17	Study on Stereoselective Pharmacokinetics of Carvedilol in Japanese Patients. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , <b>2006</b> , 32, 772-775	0.1	
16	βBlockers. <b>2008</b> , 139-149		
15	Ein integrativer Bezugsrahmen zur Analyse der Dynamik der Geschäftsbeziehungen in professionellen Dienstleistungsmärkten. <b>1997</b> , 122-245		
14	Geschäftsbeziehungen in professionellen Dienstleistungsmärkten als verhaltenswissenschaftliche Erkenntnisobjekte. <b>1997</b> , 62-121		
13	Pharmaka mit Wirkung auf das vegetative System. <i>Springer-Lehrbuch</i> , <b>1997</b> , 73-111	0.4	
12	Pharmaka mit Wirkung auf das vegetative System. <i>Springer-Lehrbuch</i> , <b>1999</b> , 73-111	0.4	
11	Physicochemical and pharmacological evaluation of carvedilol-eudragit RS100 electrospayed nanostructures. <i>Iranian Journal of Basic Medical Sciences</i> , <b>2019</b> , 22, 547-556	1.8	2
10	ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR KNOWN AND UNKNOWN IMPURITIES PROFILING FOR CARVEDILOL PHARMACEUTICAL DOSAGE FORM (TABLETS). <i>International Journal of Current Pharmaceutical Research</i> , 71-80	0.2	
9	Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 611, 121302	6.5	1
8	βAdrenoceptor Antagonists. <b>2021</b> ,		
7	DEGRADATION KINETICS OF CARVEDILOL PHARMACEUTICAL DOSAGE FORMS (TABLETS) THROUGH STRESS DEGRADATION STUDY. <i>International Journal of Current Pharmaceutical Research</i> , 54-59	0.2	0
6	Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia Syndrome as a Clinical Profile Leading to the Diagnosis of Transthyretin Amyloidosis: A Report of Two Cases. <i>Cureus</i> , <b>2022</b> ,	1.2	
5	UHPLC Enantiomer Resolution for the βAdrenoceptor Antagonist R/S-Carvedilol and Its Major Active Metabolites on Chiralpak IB N-5. <b>2022</b> , 27, 4998		0
4	High-Shear Wet Granulation of SMEDDS Based on Mesoporous Carriers for Improved Carvedilol Solubility. <b>2022</b> , 14, 2077		1
3	Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis following voluntary carvedilol poisoning in a subject with cirrhosis: a case report.		0
2	In Vitro Permeation Studies on Carvedilol Containing Dissolving Microarray Patches Quantified Using a Rapid and Simple HPLC-UV Analytical Method. <b>2022</b> , 23,		0
1	Buccal films: A review of therapeutic opportunities, formulations & relevant evaluation approaches. <b>2022</b> , 352, 1071-1092		0